China Biologic's International Sales Raise Company Margins

| About: China Biologic (CBPO)

China Biologic Products, Inc. (NASDAQ:CBPO) has a contract to ship $1.6 million worth of its plasma-based products to India. The products, which will be sold under China Biologic’s name, have been registered under the Central Drugs Standard Control Organization (CDSCO), the drug control administration in India. China Biologic recently began an initiative to ramp up its international sales.

The products include Human Hepatitis B Immunoglobulin 100IU/200IU and Human Immunoglobulin (ph4) for IV Injection (IVIG) 2.5gm/5.0gm. The first part of the shipment has been delivered, and the entire order is expected to be complete before January 31, 2009.

China Biologic also announced that, under its international sales initiative, the company has also delivered a sample order of Human Rabies Immunoglobulin to an authorized biopharmaceutical distributor in Macao.

Mr. Chao Ming Zhao, CEO of China Biologic Products, said the international sales, in addition to increasing the company’s revenues, also represent higher margins, because prices in international markets are higher than they are in China.

Disclosure: none.